Armistice Capital, LLC Supernus Pharmaceuticals, Inc. Transaction History
Armistice Capital, LLC
- $7.34 Billion
- Q1 2024
A detailed history of Armistice Capital, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Armistice Capital, LLC holds 3,572,000 shares of SUPN stock, worth $94.7 Million. This represents 1.66% of its overall portfolio holdings.
Number of Shares
3,572,000
Previous 4,650,000
23.18%
Holding current value
$94.7 Million
Previous $135 Million
9.46%
% of portfolio
1.66%
Previous 1.9%
Shares
18 transactions
Others Institutions Holding SUPN
# of Institutions
261Shares Held
57.3MCall Options Held
84.1KPut Options Held
61.2K-
Black Rock Inc. New York, NY10.4MShares$275 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$165 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C32.67MShares$70.8 Million0.1% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.56MShares$67.8 Million0.02% of portfolio
-
State Street Corp Boston, MA2.04MShares$54 Million0.0% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.42B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...